Canadian Pharmacy Blog

The FDA has approved adalimumab (Humira®, Abbott) for reducing signs and symptoms of active arthritis in patients with psoriatic arthritis (PsA). PsA is a chronic autoimmune disease that combines the symptoms of arthritis (joint pain and inflammation) with those of psoriatic skin disease (dry, scaly skin). It is the first new disease indication for this [...]

The FDA has approved an expanded indication for the human monoclonal antibody adalimumab (Humira, Abbott) that includes inhibiting structural joint damage and improving physical function in patients with psoriatic arthritis (PsA). This indication is in addition to the approval for PsA that was granted in October 2005. This product is also approved for moderate-to-severe rheumatoid [...]